Drugs / PV-10
PV-10
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01760499 | Jan 2013 → Dec 2015 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00237354 | Oct 2005 → Jun 2008 | breast cancer | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00219843 | Aug 2005 → Aug 2007 | melanoma | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02557321 | Oct 2015 → May 2023 | melanoma | Provectus Biopharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00521053 | Sep 2007 → May 2010 | melanoma | Provectus Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02288897 | Apr 2015 → Apr 2019 | cutaneous melanoma | Provectus Biopharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase not stated1 trial | ||||||
| — | NCT01260779 | — | skin neoplasm | Provectus Biopharmaceuticals, Inc. | No longer available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PV-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00219843 ↗ |
| Known as | rose bengal disodium | “Drug: PV-10 (10% rose bengal disodium)” NCT02288897 ↗3“PV-10 (rose bengal disodium, 10%)” NCT00219843 ↗ “PV-10 (10% rose bengal disodium)” NCT00521053 ↗ “PV-10 (10% rose bengal disodium)” NCT01260779 ↗ |
| Known as | rose bengal disodium 10% | “PV-10 (rose bengal disodium 10%)” NCT00237354 ↗ |
| Route | Other | “Intralesional injection for chemoablation” NCT00521053 ↗ |